Jasper Therapeutics Reports Warrant Offer Results

The biotech company says holders tendered 68.94% of outstanding warrants under its cash purchase offer.

Updated on Nov. 9, 2026 in Biotech

Jasper Therapeutics Reports Warrant Offer Results

Jasper Therapeutics, a clinical stage biotechnology company focused on immune-mediated diseases, announced the results of its offer to purchase warrants issued in a September 2025 underwritten public offering. A total of 8,510,658 warrants were properly tendered and not properly withdrawn.

Why it matters

The tender offer lets the company retire a large share of its outstanding warrants at a fixed cash price of $0.324 per warrant. Holders who tendered received cash rather than waiting on the warrants' future value.

Approximately 68.94% of outstanding warrants were tendered, totaling 8,510,658 warrants at $0.324 each. The announcement does not address the remaining warrants still held outside the offer.

The players

Jasper Therapeutics

Jasper Therapeutics is a clinical stage biotechnology company developing treatments for immune-mediated diseases.

The details

The offer to purchase warrants expired at 12:00 a.m. Eastern Time on November 7, 2026, and the company said it expects to pay $2,757,453.19 in cash for the tendered warrants, with payment to be made promptly. The offer was made through an Offer to Purchase, a Letter of Transmittal and a Schedule TO filed with the SEC.

Timeline

  1. September 18, 2025: Warrants were issued and sold in an underwritten public offering.

  2. October 7, 2026: The Schedule TO was originally filed with the SEC.

  3. November 7, 2026: The offer to purchase warrants expired at 12:00 a.m. Eastern Time.

  4. November 9, 2026: The company announced the results of the offer.

Big Picture

Warrants issued in underwritten offerings are often repurchased or exercised as companies manage their capital structure. This tender offer follows that pattern by converting a portion of outstanding warrants into cash.

Holders of warrants that were not tendered remain subject to the original warrant terms. The payment of $2,757,453.19 to tendering holders is scheduled to be made promptly after the offer's expiration.

The takeaway

Warrant tender offers can give companies a way to reduce outstanding warrant obligations while providing holders a cash exit at a set price. Readers tracking biotech financing should watch how remaining warrant holdings are handled.

Further reading

Explore more biotech news coverage from the Redwood City area.

Source note: This article includes information reported by The Manila times.